Abstract
The effects of dopaminergic receptor inhibitors such as thiothixine (D1/D2), fluphenazine (D1/D2), trifluoperazine (D1/D2), pimozide (D2), flupenthixol (D1/D2), (+/−)-SKF 83566 (D1), and spiperone (D2) on splenic natural killer (NK) cell cytotoxic activities were assessed in vitro using mouse spleen lymphocytes or enriched NK cells. Both the activities of the splenic NK cell cytotoxicity and the effector-target cell conjugation were suppressed by thiothixine, fluphenazine, and trifluoperazine at concentrations from 2.64 to 14.78 μM. In addition, the augmentation of the cytolytic activity of NK cells induced by interferon-α or interleukin-2 was antagonized by pretreatment with these neuroleptic compounds. However, neither the splenic NK cell cytotoxicity nor the effector-target cell conjugation were affected by treatment with other neuroleptic compounds such as pimozide, flupenthixol, (+/−)-SKF 83566, and spiperone. Thus, it appears that neuroleptic compounds such as thiothixine, fluphenazine, and trifluoperazine may act through the mechanisms other than a dopaminergic pathway to affect the NK cell-target cell interaction.
Similar content being viewed by others
References
Descotes, J., in: Immunotoxicology of Drugs and Chemicals, p. 129. Ed J. Descotes. Elsevier, Amsterdam 1988.
Ferguson, R. M., Schmiditke, J. R., and Simmons, R. L., Nature256 (1975) 744.
Descotes, R., Tedone, R., and Evreuy, J. C. L., J. Neuroimmun.9 (1985) 81.
Stavitsky, A. B., Dasch, J. R., and Astrachan, L., Cell. Immun.87 (1984) 411.
Roudebush, R. E., Berry, P. L., Layman, N. K., Butler, L. D., and Bryant, H. U., Int. J. Immunopharmac.13 (1991) 961.
Descotes, J., and Evreux, J. C. L., Experientia37 (1981) 1004.
Herberman, R. B., and Holden, H. T., Adv. Cancer Res.27 (1978) 305.
Herberman, R. B., in: Nature Cell-mediated Immunity against Tumors, p. 1321. Ed. R. B. Herberman. Academic Press, New York 1980.
Ching, C., and Lopez, C., Infect. Immun.26 (1978) 49.
Ortaldo, J. R., Pathol. Immunopathol. Revs.5 (1986) 203.
Katz, P., Zaytoun, A. M., and Fauci, A. S., J. Immun.129 (1978) 287.
Locke, S., and Krans, L., in: Biological Mediators of Behavior and Disease: Neoplasia. Ed. S. M. Levy. Elsevier Biomedical, New York 1982.
Hellstrand, K., Hermodsson, S., and Strannegard, O., J. Immun.134 (1985) 4095.
Steele, T. A., and Brahmi, Z., J. Immun.141 (1988) 3164.
Won, S. J., and Lin, M. T., Int. J. Immunopharmac.11 (1989) 451.
Patel, M. R., and Linna, T. J., Immunology53 (1984) 721.
Saito, T., Welker, R. D., Fukui, H., Herberman, R. B., and Chirigos, M. A., Cell. Immun.90 (1985) 577.
Leung, K. H., and Ip, M. M., Int. J. Immunopharmac.7 (1985) 857.
Nitta, T., Yagita, H., Sato, K., and Okumura, K. J., Expl Med.170 (1989) 1757.
Biron, C. A., Sonnenfeld, G., and Welsh, R. M., J. Leukocyte Biol.35 (1984) 31.
Suzuki, R., Handa, H. I., and Kumagai, K., J. Immun.130 (1983) 981.
Riccardi, C., Vose, M. B., and Herberman, R. B., J. Immun.130 (1983) 228.
Kuribayashi, K., Gillis, S., Kern, D. E., and Henney, C. S., J. Immun.126 (1981) 2321.
Ellis, T. M., McKenzie, R. S., Simms, P. E., Helfrich, B. A., and Fisher, R. E., J. Immun.143 (1989) 4282.
Ortaldo, J. R., and Herberman, R. B., in: Immunobiology of Natural Killer Cells, vol. 2. p. 145. Eds E. Lotzova, R. B. Herberman. CRC Press, Boca Raton, FL 1986.
Djeu, J. Y., Stocks, N., Varesio, L., Holden, H. T., and Herberman, R. B., Cell. Immun.58 (1981) 49.
Robertson, M. J., Caligiuri, M. A., Manley, T. J., Levine, H., and Ritz, J., J. Immun.154 (1990) 3184.
Zarcone, D., Prasthofer, E. F., Malavasi, F., Pistoia, V., LoBuglio, A. F., and Grossi, C. E., Blood69 (1987) 1725.
Manyak, C. L., Norton, G. P., Lobe, C. G., Bleackley, R. C., Gershenfeld, H. K., Weissman, I. L., Kumar, V., Signal, N. H., and Koo, G. C., J. Immun.142 (1989) 3707.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Won, S.J., Chuang, Y.C., Huang, W.T. et al. Suppression of natural killer cell activity in mouse spleen lymphocytes by several dopamine receptor antagonists. Experientia 51, 343–348 (1995). https://doi.org/10.1007/BF01928892
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01928892